MediciNova, Inc.
Methods and dosing regimens using ibudilast and a second agent for cancer therapy

Last updated:

Abstract:

Methods and dosing regimens for treating glioblastoma or recurrent glioblastoma and its associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) or a pharmaceutically acceptable salt thereof and at least one or more other therapeutic agent.

Status:
Grant
Type:

Utility

Filling date:

11 Feb 2019

Issue date:

18 Aug 2020